Mechanism of action of fibrates on lipid and lipoprotein metabolism.

@article{Staels1998MechanismOA,
  title={Mechanism of action of fibrates on lipid and lipoprotein metabolism.},
  author={Bart Staels and Jean Dallongeville and Johan Auwerx and Kristina Schoonjans and Eran Leitersdorf and J-C. Fruchart},
  journal={Circulation},
  year={1998},
  volume={98 19},
  pages={
          2088-93
        }
}
Treatment with fibrates, a widely used class of lipid-modifying agents, results in a substantial decrease in plasma triglycerides and is usually associated with a moderate decrease in LDL cholesterol and an increase in HDL cholesterol concentrations. [] Key Result The PPAR-alpha form mediates fibrate action on HDL cholesterol levels via transcriptional induction of synthesis of the major HDL apolipoproteins, apoA-I and apoA-II.

Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators

TLDR
Observations have provided the molecular basis leading to a better understanding of the mechanism of action of fibrates and glitazones on lipid and lipoprotein metabolism and identify PPARs as attractive targets for the rational design of more potent lipid-lowering drugs.

Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice*

TLDR
A novel effect of fibrates on hepatic SR-BI expression is described providing an alternative mechanism by which this drug family modulates HDL metabolism in vivo.

Effects of Fibrate Drugs on Expression of ABCA1 and HDL Biogenesis in Hepatocytes

TLDR
It is concluded that fibrates enhance expression of ABCA1 in hepatocytes to contribute to increase of the HDL biogenesis in a PPAR-dependent manner, whether exclusively or nonexclusively on PPARα.

Peroxisome Proliferator-activated Receptor α Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil*

TLDR
Results show major molecular differences in action between fibrates and fish oil providing a molecular rationale for combination treatment with these compounds.

Mechanisms of triglyceride metabolism in patients with bile acid diarrhea.

TLDR
There is currently minimal clinical data on triglyceride metabolism in patients with bile acid diarrhoea (BAD), and emerging data suggests that a third of patients with BAD have hypertriglyceridemia.

High density lipoprotein turnover is dependent on peroxisome proliferator-activated receptor α in mice.

TLDR
The plasma HDL turnover rate is retarded in PPARα-null mice, perhaps more prominently in females, including HDL properties being consistent with its slow turnover.

Chemistory of Fibrates.

TLDR
Various targets of fibrate action, biochemical pathways and commonalities in potential molecular interactions are discussed, including links to diabetes and diabetic complications.
...

References

SHOWING 1-10 OF 97 REFERENCES

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

TLDR
In humans fibrates increase plasma apo A-II concentrations by inducing hepatic apo B-II production, thereby demonstrating the pivotal role of PPAR in controlling human lipoprotein metabolism.

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.

TLDR
It is suggested that PPARs are key messengers responsible for the translation of nutritional and pharmacological stimuli into changes in gene expression and differentiation pathways.

Effects of Gemfibrozil and Other Fibric Acid Derivatives on Blood Lipids and Lipoproteins

TLDR
There is evidence that oral gemfibrozil (Lopid®, Parke—Davis, Morris Plains, NJ) can reduce the risk of serious coronary events, specifically in patients who had elevations of both LDL cholesterol levels and total plasma triglyceride levels with lower HDL cholesterol levels.

Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators*

TLDR
Thiazolidinedione antidiabetic agents seem to favor adipocyte-specific FA uptake relative to muscle, perhaps underlying in part the beneficial effects of these agents on insulin-mediated glucose disposal.

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ

TLDR
It is shown here that specific FAs, eicosanoids, and hypolipidemic drugs are ligands for PPARα or PPARδ, and a novel conformation-based assay is developed that screens activators for their ability to bind to PPAR α/δ and induce DNA binding.

The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression.

TLDR
Results dictate an expanded role for the PPAR in the regulation of FA metabolism and indicates that intracellular FA metabolites that accumulate during inhibition can regulate MCAD expression and are likely candidates for PPAR ligand(s).

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ

TLDR
Evidence that PPARs serve as physiological sensors of lipid levels is provided and a molecular mechanism whereby dietary fatty acids can modulate lipid homeostasis is suggested.

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.

TLDR
It is shown that certain mono- and polyunsaturated fatty acids bind directly to PPARalpha and PPARgamma at physiological concentrations, and that the eicosanoids 8(S)-hydroxyeicosatetraenoic acid and 15-deoxy-Delta12,14-prostaglandin J2 can function as subtype-selective ligands for PPAR alpha and PPARS, respectively.
...